Neuronetics_logo-RGB purple.png
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
08. Januar 2024 08:30 ET | Neuronetics
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics_logo-RGB purple.png
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
18. Dezember 2023 08:49 ET | Neuronetics
MALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
04. Dezember 2023 08:56 ET | Neuronetics
MALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
15. November 2023 16:15 ET | Neuronetics
MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
13. November 2023 08:57 ET | Neuronetics
MALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics_logo-RGB purple.png
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
09. November 2023 08:32 ET | Neuronetics
MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Third Quarter 2023 Financial and Operating Results
07. November 2023 07:30 ET | Neuronetics
MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics_logo-RGB purple.png
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06. November 2023 16:30 ET | Neuronetics
MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
24. Oktober 2023 08:30 ET | Neuronetics
MALVERN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics_logo-RGB purple.png
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
16. Oktober 2023 08:56 ET | Neuronetics
MALVERN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...